Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 4158-4164

  Palayoor, Sanjeewani T ^a   Burgos, Melissa A ^a   Shoaibi, Azadeh ^a   Tofilon, Philip J ^a   Coleman, C Norman ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; IBUPROFEN; PROTEIN INHIBITOR; RADIOSENSITIZING AGENT;

ANIMAL CELL; ARTICLE; CANCER RADIOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR HYPOXIA; TUMOR SUPPRESSOR GENE; VHL GENE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CARCINOMA; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IBUPROFEN; IMMUNOBLOTTING; KIDNEY NEOPLASMS; MUTATION; OXYGEN; PROGNOSIS; RADIATION TOLERANCE; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 3042535856     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0005     Document Type: Article

References (51)

1. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-78.
2. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor-1α in common human cancers and their metastases Cancer Res 1999;59:5830-5.
3. Harris AL. Hypoxia-a key regulator in tumor growth. Nat Rev Cancer 2001;2:38-46.
4. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relationship of hypoxia inducible factor 1a and 2a in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 2001;85:881-90.
5. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI. Association of hypoxia-inducible factors 1a and 2a with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer (Phila) 2002;95:1055-63.
6. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF-1A and HIF-2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-202.
7. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94: 8104-9.
8. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1a in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8.
9. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev 2003;3: 721-32.
10. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int J Oncol 2001;19:257-62.
11. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:1-9.
12. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor-1α is mediated by oxygen-dependent domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 1998;95:7987-92.
13. Ivan M, Kondo K, Yang H, et al. HIF-1α targeted for VHL-mediated destruction by prolin hydroxylation: implications for O2 sensing. Science (Wash DC) 2001;292:464-8.
14. Jaakkola P, Mole DR, Tian Y, et al. Targeting HIF-1α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (Wash DC) 2001;292:468-72.
15. Cockman ME, Masson N, Mole DR, et al. Hypoxia indicible factor-α binding and ubiquitylation by von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;33:25733-41.
16. Wang GL, Jing BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-4.
17. Salceda S, Caro J. Hypoxia-inducible factor-1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J Biol Chem 1997;272:22642-7.
18. Jiang BH, Agani F, Passaniti A, Semenza GL. V-scr induces expression of hypoxia-inducible factor-1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase-1-involvement of HIF-1 in tumor progression. Cancer Res 1997;57: 5328-35.
19. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1α expression by epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
20. Maxwell PH, Wiesner, Chang GW, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond) 1999;399:271-5.
21. Kaelin WG, Maher ER. The VHL tumor-suppressor gene paradigm. Trends Genet 1998;14:423-6.
22. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1a and HIF-2a under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435-43.
23. Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourogenesis in von Hippel-Lindau disease. Human Mol Genetics 2001;101029-38.
24. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Landau gene mutation. Cancer Res 2002;62: 2957-61.
25. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumor suppressor by mRNA differential expression profiling. Oncogene 2000;19:6297-305.
26. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Sci USA 1996;93:10589-94.
27. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-62.
28. Palayoor ST, Bump EA, Calderwood SK, Bartol S, Coleman CN. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res 1998;4:763-71.
29. Teicher BA, Bump EA, Palayoor ST, Northey D, Coleman CN. Signal transduction inhibitors as modifiers of radiation therapy in prostate carcinoma xenografts. Radiat Oncol Investig 1996;4:221-30.
30. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res 2003;9:3150-7.
31. Isaacs JS, Jung Y, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277: 29936-44.
32. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
33. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF-1α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1:247-55.
34. Albright N. Computer programs for the analysis of cellular survival data. Radiat Res 1987;112:331-40.
35. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumor hypoxia, chemotherapeutic resistance and hypoxia related therapies. Cancer Treatment Rev 2003;29:297-307.
36. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervical cancer. Radiother Oncol 1998;48:149-56.
37. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
38. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
39. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
40. Beasley NJP, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002;62:2493-7.
41. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1a indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234-40.
42. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1a is associated with unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831-7.
43. Abersold DM, Burri PB, Beer KT, et al. Expression of hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-6.
44. Gorospe M, Egan JM, Zbar B, et al. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol Cell Biol 1999;19:1289-300.
45. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1a is a negative factor for tumor therapy. Oncogene 22:3213-20.
46. Baba M, Hirai S, Kawakami S, et al. Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. Oncogene 2001;20:2727-36.
47. Jones MK, Szabo IL, Kawanaka H, Husain SS, Tarnawski AS. von Hippel-Lindau tumor suppressor and HIF-1a: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002; 16:264-6.
48. Gray LH, Conger AD, Hornsey S, Scott OC. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
49. Russo A, Mitchell JB, Finkelstein E, DeGraff WG, Spiro IJ, Gamson J. The effect of cellular glutathione elevation on the oxygen enhancement ratio. Radiat Res 1985;103:232-9.
50. Hall EJ. The oxygen effect and reoxygenation. In: Hall EJ, editor. Radiobiology for the radiologist. Philadelphia: Lippincott Williams and Wilkins, 2000. pp. 91-111
51. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase-1-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-82.